BMGL

Basel Medical Group Ltd Ordinary Shares
BMGL
Market cap $92.3M

5.00 USD

+0.12

2.46%

At close Apr 1, 4:00 PM EDT

1 day

2.46%

5 days

20.48%

1 month

19.05%

3 months

12.61%

6 months

12.61%

Year to date

12.61%

1 year

12.61%

5 years

12.61%

10 years

12.61%

About: Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.

Healthcare Offices & Clinics of Doctors of Medicine

–

Funds holding %

of 7,398 funds

–

Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BMGL.

See Analyst Rankings

Financial journalist opinion

Basel Medical Group Ltd Announces Exercise of Overallotment Option

Singapore, March 19, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the full exercise of the overallotment option by the representative of the underwriters of its initial public offering to purchase an additional 330,750 ordinary shares at a price of US$4.00 per share and the closing of such issuance. The shares of the Company commenced trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol “BMGL”.

Basel Medical Group Ltd Announces Exercise of Overallotment Option

Basel Medical Group Ltd Announces Closing of US$8,820,000 Initial Public Offering

Singapore, March 03, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the closing of its initial public offering of 2,205,000 ordinary shares at a public offering price of US$4.00 per share. The shares commenced trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol “BMGL”. The Company has registered for resale up to 2,000,000 existing ordinary shares by certain selling shareholders. The Company will not receive any proceeds from the sale of those shares by the selling shareholders.

Basel Medical Group Ltd Announces Closing of US$8,820,000 Initial Public Offering

U.S. IPO Weekly Recap: Small Asia-Based Names List, As TV Adtech MNTN And Others Join The Pipeline

Four IPOs and four SPACs listed this week. Four IPOs and two SPACs submitted initial filings. The March IPO market is set to start off with a quiet week.

U.S. IPO Weekly Recap: Small Asia-Based Names List, As TV Adtech MNTN And Others Join The Pipeline

Basel Medical Group Ltd Prices US$8,820,000 Initial Public Offering

Singapore, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (the “Company”) (Nasdaq: BMGL), a Singapore-based clinical provider of general and subspecialized orthopedic and trauma services, sports medicine and surgery, orthopedic procedures, as well as neurosurgical treatments, today announced the pricing of its initial public offering of 2,205,000 ordinary shares at a public offering price of US$4.00 per share. The shares are expected to commence trading on the Nasdaq Capital Market on February 25, 2025, under the ticker symbol “BMGL”. Concurrently, the Company has registered for resale up to 2,000,000 existing ordinary shares by certain selling shareholders. The Company will not receive any proceeds from the sale of those shares by the selling shareholders.

Basel Medical Group Ltd Prices US$8,820,000 Initial Public Offering

See News Rankings

Charts implemented using Lightweight Charts™